ROCKVILLE, Md., Feb. 17, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today released the following letter to shareholders:
Having just completed a very important licensing and joint venture agreement to more rapidly move our ophthalmic drug candidate forward in the U.S., we would like to take this time to report on the status of RegeneRx and the exciting prospects for both the short term and long term future of our company. This letter is intended to be a top-line synopsis, rather than a comprehensive analysis, of the various partnerships in which we are engaged as well as our operations and future direction. We will also identify key clinical milestones and inflection points from now through 2016. We reserve the right to modify our goals and expectations from time to time in accordance with clinical development, partnering activities, access to capital markets, and the general climate in the pharmaceutical industry.
For the past several years, RegeneRx has been implementing a strategy to leverage our clinical assets by engaging in product development and commercial partnerships, given our limited access to capital. During this period, we continued to support research and development with Thymosin beta 4 (Tβ4) by working with more than 50 leading academic and medical institutions in the U.S. and Europe to conduct research intended to supplement and/or expand our clinical efforts. As a result, our clinical progress and partnering activities have progressed in a manner that now enables us to move expeditiously toward product commercialization...
To view the entire letter to shareholders, please go to www.regenerx.com or click on the following link: http://regenerx.investorroom.com/image/Letter+to+Shareholders+2015+Final.pdf.
Forward Looking Statements
Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking statements in this shareholder letter include, but are not limited to, statements regarding our strategic and research partnerships, future royalty and milestone payments, regulatory applications and approvals, the development of our drug candidates, the use of our drug candidates to treat various conditions, our growth strategy, and our financial needs. The proposed clinical trials and costs and resources to support such trials, as well as the other forward-looking statements, are expectations and estimates based upon information obtained and calculated by the Company at this time and are subject to change. Moreover, there is no guarantee any of these trials will be successful or confirm previous clinical results. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this shareholder letter represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
SOURCE RegeneRx Biopharmaceuticals, Inc.